RET fusions are driver alterations found in several solid tumour types, including thyroid cancer subsets (5–10%), non-small-cell lung cancer (NSCLC; 1–2%) and other solid tumour types (<1%). In the phase I/II LIBRETTO-001 trial, the RET kinase inhibitor selpercatinib showed activity in selected RET fusion-positive cancers, leading to an FDA Accelerated Approval of this drug for patients aged ≥12 years with RET fusion-positive thyroid cancer or NSCLC. Now, updated data from this trial confirm the efficacy of selpercatinib in NSCLC and show promising activity in other types of RET fusion-positive solid tumours.